Loading institutional data...
Loading institutional data...
Held by 196 of 5,944 reporting institutions (91th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| PGEN | $2.8B | — | — | 287.6× | 147% | — | -2588% | -1199% | -220% | -0.9× | 196 |
Peers = companies sharing PGEN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M 100.0% | $3.9M 100.0% | $6.2M 100.0% | $26.9M 100.0% | $14.3M 100.0% | $32.0M 100.0% | $90.7M 100.0% | $151.2M 100.0% | $231.0M 100.0% | $190.9M 100.0% |
| Cost of Revenue | — | — | — | — | — | — | — | — | $33.3M 14.4% | $37.7M 19.8% |
| Cost of Products | — | — | — | — | — | — | — | — | $33.3M 14.4% | $37.7M 19.8% |
| Cost of Services | — | — | — | — | — | — | — | — | $29.5M 12.8% | $23.9M 12.5% |
| Research & Development | $41.3M 426.8% | $53.1M 1352.1% | $48.6M 780.9% | — | — | — | — | $404.6M 267.6% | $143.2M 62.0% | $112.1M 58.7% |
| Selling, General & Admin | $70.1M 724.2% | $41.3M 1052.1% | $40.4M 649.2% | — | — | — | — | $137.8M 91.2% | $146.1M 63.3% | $142.3M 74.5% |
| Total Operating Expenses | $120.2M 1241.1% | $139.0M 3540.2% | $106.0M 1702.5% | — | — | — | — | $666.2M 440.7% | $368.9M 159.7% | $316.1M 165.6% |
| Operating Income | -$110.5M -1141.1% | -$135.0M -3440.2% | -$99.8M -1602.5% | — | — | — | — | -$505.6M -334.4% | -$137.9M -59.7% | -$125.2M -65.6% |
| Interest Expense | $3.9M 39.9% | $6K 0.2% | $468K 7.5% | — | — | — | — | $8.5M 5.6% | $611K 0.3% | $861K 0.5% |
| Other Income (Expense), net | -$140.1M -1447.0% | $7.0M 178.4% | $3.4M 54.6% | — | — | — | — | -$19.0M -12.6% | $22.5M 9.7% | -$47.9M -25.1% |
| Pretax Income | -$250.6M -2588.2% | -$128.0M -3261.9% | -$96.4M -1548.0% | -$80.0M -297.2% | -$111.0M -777.8% | -$104.5M -326.7% | -$171.3M -188.8% | -$395.9M -261.9% | -$78.4M -33.9% | -$194.2M -101.7% |
| Income Tax Expense | $3K 0.0% | -$1.8M -45.7% | -$458K -7.4% | -$189K -0.7% | -$160K -1.1% | -$82K -0.3% | -$930K -1.0% | -$15.4M -10.2% | $2.1M 0.9% | -$3.9M -2.0% |
| Net Income | -$250.6M -2587.8% | -$126.2M -3215.3% | -$95.9M -1540.6% | $28.3M 105.2% | -$92.2M -646.2% | -$170.5M -533.0% | -$322.3M -355.3% | -$509.3M -336.9% | -$117.0M -50.7% | -$186.6M -97.7% |
| Per Share | ||||||||||
| EPS (Basic) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 | $-1.02 | $-2.09 | — | — | — |
| EPS (Diluted) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 | $-1.02 | $-2.09 | — | — | — |
| Weighted Avg Shares (Basic) | 313.0M | 267.7M | 244.5M | 200.4M | 197.8M | 167.1M | 154.1M | — | — | — |
| Weighted Avg Shares (Diluted) | 313.0M | 267.7M | 244.5M | 200.4M | 197.8M | 167.1M | 154.1M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$90M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: -220%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $30M covers the $0 due within a year 30234000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-09-30 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~4.2% on $93M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 13-yr range · 100th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| R&D | 267.6 | — | — | — | — | 780.9 | 1352.1 | 426.8 |
| SG&A | 91.2 | — | — | — | — | 649.2 | 1052.1 | 724.2 |
| Operating Income | -334.4 | — | — | — | — | -1602.5 | -3440.2 | -1141.1 |
| Income Tax | -10.2 | -1.0 | -0.3 | -1.1 | -0.7 | -7.4 | -45.7 | 0.0 |
| Net Income | -336.9 | -355.3 | -533.0 | -646.2 | 105.2 | -1540.6 | -3215.3 | -2587.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PGEN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.